960 Participants NeededMy employer runs this trial

Tiespectus for Age-Related Macular Degeneration

(TORRONTES Trial)

Recruiting at 8 trial locations
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD).

Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD.

The goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.

Who Is on the Research Team?

MD

Medical Director

Principal Investigator

Merck Sharp & Dohme LLC

Are You a Good Fit for This Trial?

Inclusion Criteria

I have not received treatment for new blood vessel growth in my eye from AMD.
I was diagnosed with wet age-related macular degeneration within the last 21 days.

Exclusion Criteria

History of uveitis in either eye
I have had macular laser treatment in my study eye before.
I have had VEGF or other eye injections in my study eye before.
See 4 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive 3 initial administrations of tiespectus or aflibercept every 4 weeks, then continue every 8 weeks until week 48

48 weeks
3 visits (in-person) every 4 weeks, then every 8 weeks

Extended Treatment

Participants continue treatment at intervals determined based on individualized response to treatment, up to week 92

44 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Tiespectus

How Is the Trial Designed?

3

Treatment groups

Experimental Treatment

Active Control

Group I: Tiespectus Low DoseExperimental Treatment1 Intervention
Group II: Tiespectus High DoseExperimental Treatment1 Intervention
Group III: Aflibercept 2 mgActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

EyeBiotech Ltd.

Lead Sponsor

Trials
3
Recruited
1,100+